542 results about "Medical therapy" patented technology

Ergonomic systems which provide medical therapy, comfort and enhanced function are provided. Surfaces are provided with adjustable contour, transient force damping and temperature. The technologies are applied to footwear, seating surfaces an cryotherapy devices. The cooling and cryotherapy system employ an evaporator in close proximity to skin, and therefore employ methods to reduce risk of frostbite. Advanced control and power supply options are disclosed.

An energy emitting apparatus for providing a medical therapy includes one or more energy generators, a logic controller electrically connected to the one or more energy generators, and one or more sensors for detecting electric conduction in a target nerve that are connected to the logic controller. The one or more energy generators produce energy focused on the target nerve upon receiving a signal from the logic controller, and the energy is varied by the logic controller according to an input provided by the one or more sensors. In one embodiment, the energy emitting apparatus is an apparatus for magnetic induction therapy that includes one or more conductive coils disposed in an ergonomic housing that produce a magnetic field focused on the target nerve upon receiving an electric current from the logic controller based on an input provided by the one or more sensors.

Ergonomic systems which provide medical therapy, comfort and enhanced function are provided. Surfaces are provided with adjustable contour, transient force damping and temperature. The technologies are applied to footwear, seating surfaces an cryotherapy devices. The cooling and cryotherapy system employ an evaporator in close proximity to skin, and therefore employ methods to reduce risk of frostbite. Advanced control and power supply options are disclosed.

A cost estimation tool, preferably a handheld computer, prices and evaluates the financial impact of new residents' prior to admission. Immediate access to this information and built-in therapeutic substitution and clinical advisories provides the opportunity to optimize pharmaceutical regimens prior to admission. In addition, an abbreviated Resource Utilization Group (RUG) evaluation function provides a rapid assessment tool to project reimbursement under the Medicare Prospective Payment System (PPS). A user may enter a complete drug regimen and estimate the costs for the regimen. Similarly, managed care reimbursement from managed care organizations (MCOs) to be analyzed. Also, drug cost may be estimated through a MEDICAID Preferred Drug List database that identifies potential Non-Preferred drugs that may be non-compensable. The present invention further transmits results wirelessly to health care providers.

Ergonomic systems which provide medical therapy, comfort and enhanced function are provided. Surfaces are provided with adjustable contour, transient force damping and temperature. The technologies are applied to footwear, seating surfaces an cryotherapy devices. The cooling and cryotherapy system employ an evaporator in close proximity to skin, and therefore employ methods to reduce risk of frostbite. Advanced control and power supply options are disclosed.

The present disclosure relates to improved capabilities for stabilizing and regulating atrial pressure with a shunt in the atrial septum or a stent in the coronary sinus. The disclosure also includes sensing, monitoring, drug therapy and control capabilities to provide improved treatment of patients with heart disease and other cardiac related conditions.

The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides for the use of the compounds of formula (I)-(XIII) in treating cancer in mammals (e.g., humans), as well inhibiting tumor cell growth in such mammals. The present invention also provides for methods of inhibiting FAS. The methods include contacting FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of inhibiting the TE domain of the FAS. The methods include contacting the thioesterase TE domain of the FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of treating cancer in mammals, as well as methods of inhibiting tumor cell growth in such mammals. The methods include administering a compound of formula (I)-(XIII) to a mammal in need of such treatment.

A method of evaluating and/or optimizing clinical outcomes and providing rational pharmacotherapy in an individual or animal requiring chronic drug therapy is provided.

A System manages IV pumps so that clinicians automatically receive alerts, decisions, and actions required to maintain a patient IV medication therapy according to a prescribed treatment protocol. An infusion pump monitoring system, includes an acquisition processor for acquiring fluid infusion parameters comprising a patient identifier, infusion fluid identifier and a rate of fluid infusion, for administration of an infusion fluid to a patient at a point of care using an infusion pump. The system also includes a repository of patient medical record information. A fluid infusion monitor uses acquired fluid infusion parameters for automatically searching a patient medical record in the repository for information concerning rate of fluid infusion of a particular infusion fluid and determining if a rate of a previously administered dose of the particular infusion fluid was lower than a rate indicated in the fluid infusion parameters. An interface processor automatically initiates generation of a message indicating a potential adverse reaction to the particular infusion fluid in response to a determination of a lower rate being employed for previously administering the particular infusion fluid.

An MRI-compatible electronic medical therapy system is provided for temporarily preventing current flow through an implanted lead wire in the presence of an induced radio frequency, magnetic, or static field. One or more normally closed switches are disposed in series between the AIMD and the one or more distal electrodes. The switch may be incorporated in the AIMD, lead wire, or within or adjacent to the electrode. The switch remains closed during normal AIMD-related therapy, but temporarily opens in the presence of an induced radio frequency, magnetic, or static field so as to prevent current flow through the electrode and lead wire. The switches prevent current from circulating that could be induced by a medical therapeutic diagnostic device, which can cause overheating of lead wires, excessive currents or temperatures and tissue damage.

Systems and methods provide for assessing a patient's hemodynamic response to a drug therapy. A patient's hemodynamic response to a drug therapy is monitored using sensor data acquired using one or more sensors. The patient's hemodynamic response to the drug therapy is quantified, such as by quantifying a patient's sensitivity or refractoriness to the drug therapy. The quantified data may be used to optimize a patient's drug therapy, among other uses.

An implantable medical device in which an electrogram is recorded and analyzed in order to detect changes indicative of cardiac ischemia. Cardiac ischemia may be detected by recording an electrogram from a sensing channel of the device and comparing the recorded electrogram with a reference electrogram. If cardiac ischemia is detected, a cardiac drug such as a thrombolytic agent is delivered.

The present invention relates to devices and methods of use thereof for detection of biomolecules, in vitro, in vivo, or in situ. The invention relates to methods of diagnosing and/or treating a subject as having or being at risk of developing a disease or condition that is associated with abnormal levels of one or more biomolecules including, but not limited to, inter alia, epilepsy, diseases of the basal ganglia, athetoid, dystonic diseases, neoplasms, Parkinson's disease, brain injuries, spinal cord injuries, and cancer. The invention also provides methods of differentiating white matter from gray matter. In some embodiments, regions of the brain to be resected or targeted for pharmaceutical therapy are identified using sensors. The invention further provides methods of measuring the neurotoxicity of a material by comparing microvoltammograms of a neural tissue in the presence and absence of the material using the inventive sensors.

A degassing module for removal of air and other gases during operation of a medical therapy device that delivers any one of hemodialysis, hemodiafiltration and hemofiltration. The degassing module has a flow-through first chamber that has a hydrophobic vent membrane that has an exterior and interior side forming a portion of the flow-through chamber. The hydrophobic vent membrane is positioned at a higher elevation on the flow-through chamber than a fluid outlet. Fluid flows through the flow-through chamber in a downward direction relative to the hydrophobic vent membrane. A flow-through chamber has a cross sectional area configured to provide for a downward flow velocity of the fluid to be less than the upward rise velocity of a smallest bubble to be removed from the fluid.

The invention is related to compositions which can be used as dermal formulations for supporting the skin to restore normal conditions in case of e.g. irritated skin, or to support medical therapy of skin with atopic dermatitis symptoms, atopic dermatitis, psoriasis or related diseases (e.g. accompanied by distorted barrier function of the skin and microbial load). The compositions of the invention can be used for dermo-cosmetic products but also for pharmaceutical/-medical products, depending on the composition and the additional actives incorporated (cosmetic actives or drugs). The invention is based on the synergistic effect of metallic particles, in particular silver particles (such as microsilver, nanosilver) and lipid particles (lipid nanoparticles or lipid microparticles). As alternatives to silver particles, other metallic particles (e.g. zinc, copper) or nanocrystalline actives can be incorporated (e.g. replacing the anti-oxidative silver by anti-oxidative nanocrystals of plant molecules such as hesperitin). This leads to combinations of lipid particles with nanocrystals for dermal use.

An implementation of a technology, described herein, for implantable medical therapy devices and techniques related to gathering and processing data field-collected by such implantable medical therapy devices. With an ICTD system and a central database, at least one embodiment of the invention, described herein, collects and analyzes data—which includes historical cardiac-status-and-treatment information—for a specific patient and adjusts a patient's therapy accordingly. With an ICTD system and a central database, at least one embodiment of the invention, described herein, collects and analyzes data—which includes historical cardiac-status-and-treatment information—for a patient population and adjusts a patient's therapy accordingly. This abstract itself is not intended to limit the scope of this patent. The scope of the present invention is pointed out in the appending claims.

A method for treating a target tissue in a patient in need thereof is provided. The method includes the steps of identifying one or more characteristics of one or more cells of a target tissue; calculating a threshold electric field for inducing IRE in the target tissue based on the one or more characteristics; constructing a treatment protocol of one or more pulse parameters, wherein the treatment protocol is capable of inducing IRE in the target tissue; and delivering the treatment protocol to the target tissue. Systems for treatment planning for medical therapies involving administering electrical treatment energy are also provided.

Compositions containing an optionally surface-functionalized mesoporous support and a biologically active agent, and pharmaceutical compositions of the same, are provided herein. Such compositions can be useful in the treatment of tumors, for example, by injection of the composition at a location near the site of the tumor.

A medical therapy system for delivering at least two therapies based on a geographic location of the medical therapy system is disclosed. The medical therapy system includes an infusion pump having a case that contains a processor, memory, a drive mechanism, a reservoir, a radio, and a sensor suite. The sensor suite includes a global positioning system (GPS) receiver to determine a location of the infusion pump. The processor receives the location of the infusion pump and executes first instructions stored in the memory. The processor executes second instructions stored in the memory only when the location of the infusion pump is within a safe zone defined around specified GPS coordinates.

The invention relates to methods, apparatus, articles-of-manufacture, and coded data signals for measuring cardiac output, limb blood flow, perfusion, blood pressure, artery elasticity, and cardiovascular deterioration and disease, including performing these measurements on a continuous heart beat-by-beat basis, for humans and animals. Unlike empirical methods of other noninvasive blood pressure concepts, the invention is grounded on scientifically appropriate hemodynamic principles that studies have validated as accurate, and is practical for wide clinical use. Devices constructed in accordance with the invention can be comfortably employed for numerous applications, including hospital monitoring, physician's office cardiovascular disease management and drug therapy monitoring, home monitoring, and athletic applications.

The invention may be implemented in a variety of single or multi-sensor embodiments, such as: invasive pressure cannula sensor systems; non invasive pressure transducer arrays and piezo or other strain sensing materials that are placed against the skin above arteries; “upstream” pulsing-sensors (that apply single or multi-frequency vibrations that are measured “downstream” from the first placement location); other types of plethysmographic sensors; sonic/ultrasonic/Doppler sensors; MRI blood spin magnetizer/sensors; oxygen sensors; and electrocardiographic sensors, etc.